Receptors, Cytoplasmic and Nuclear
"Receptors, Cytoplasmic and Nuclear" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Intracellular receptors that can be found in the cytoplasm or in the nucleus. They bind to extracellular signaling molecules that migrate through or are transported across the CELL MEMBRANE. Many members of this class of receptors occur in the cytoplasm and are transported to the CELL NUCLEUS upon ligand-binding where they signal via DNA-binding and transcription regulation. Also included in this category are receptors found on INTRACELLULAR MEMBRANES that act via mechanisms similar to CELL SURFACE RECEPTORS.
Descriptor ID |
D018160
|
MeSH Number(s) |
D12.776.260.698 D12.776.826 D12.776.930.669
|
Concept/Terms |
Receptors, Cytoplasmic and Nuclear- Receptors, Cytoplasmic and Nuclear
- Cytosol and Nuclear Receptors
- Receptors, Nuclear and Cytoplasmic
- Nuclear and Cytoplasmic Receptors
- Receptors, Cytosol and Nuclear
- Receptors, Cytosolic and Nuclear
- Cytoplasmic and Nuclear Receptors
- Cytosolic and Nuclear Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Cytoplasmic and Nuclear".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Cytoplasmic and Nuclear".
This graph shows the total number of publications written about "Receptors, Cytoplasmic and Nuclear" by people in this website by year, and whether "Receptors, Cytoplasmic and Nuclear" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 2 | 0 | 2 | 1994 | 2 | 0 | 2 | 1995 | 3 | 0 | 3 | 1996 | 1 | 0 | 1 | 1997 | 1 | 0 | 1 | 1998 | 1 | 1 | 2 | 1999 | 5 | 0 | 5 | 2000 | 2 | 4 | 6 | 2001 | 9 | 3 | 12 | 2002 | 4 | 4 | 8 | 2003 | 3 | 2 | 5 | 2004 | 3 | 2 | 5 | 2005 | 3 | 3 | 6 | 2006 | 1 | 3 | 4 | 2007 | 2 | 1 | 3 | 2008 | 5 | 1 | 6 | 2009 | 2 | 0 | 2 | 2010 | 1 | 1 | 2 | 2012 | 1 | 0 | 1 | 2013 | 1 | 1 | 2 | 2014 | 2 | 2 | 4 | 2015 | 1 | 2 | 3 | 2017 | 0 | 1 | 1 | 2018 | 2 | 0 | 2 | 2019 | 2 | 1 | 3 | 2020 | 2 | 1 | 3 | 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Cytoplasmic and Nuclear" by people in Profiles.
-
Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022 03; 76(3):506-517.
-
Wang Y, Crittenden DB, Eng C, Zhang Q, Guo P, Chung D, Fenaux M, Klucher K, Jones C, Jin F, Quirk E, Charlton MR. Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021 10; 10(10):1198-1208.
-
Howlett-Prieto Q, Langer C, Rezania K, Soliven B. Modulation of immune responses by bile acid receptor agonists in myasthenia gravis. J Neuroimmunol. 2020 12 15; 349:577397.
-
Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 07; 72(1):58-71.
-
Hight SK, Mootz A, Kollipara RK, McMillan E, Yenerall P, Otaki Y, Li LS, Avila K, Peyton M, Rodriguez-Canales J, Mino B, Villalobos P, Girard L, Dospoy P, Larsen J, White MA, Heymach JV, Wistuba II, Kittler R, Minna JD. An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis. Neoplasia. 2020 08; 22(8):294-310.
-
Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Ratziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
-
Edens BM, Vissers C, Su J, Arumugam S, Xu Z, Shi H, Miller N, Rojas Ringeling F, Ming GL, He C, Song H, Ma YC. FMRP Modulates Neural Differentiation through m6A-Dependent mRNA Nuclear Export. Cell Rep. 2019 07 23; 28(4):845-854.e5.
-
Pierre JF, Li Y, Gomes CK, Rao P, Chang EB, Yin DP. Bile Diversion Improves Metabolic Phenotype Dependent on Farnesoid X Receptor (FXR). Obesity (Silver Spring). 2019 05; 27(5):803-812.
-
Ming M, Wu W, Xie B, Sukhanova M, Wang W, Kadri S, Sharma S, Lee J, Shacham S, Landesman Y, Maltsev N, Lu P, Wang YL. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I?B. Mol Cancer Ther. 2018 12; 17(12):2564-2574.
-
Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 03 20; 36(9):859-866.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|